Development of Secondary Leukemia Associated with (1;7)(ql0;pl0) in a Patient with Crow-Fukase Syndrome

Abstract

A 42-year-old woman with Crow-Fukase syndrome developed acute myeloid leukemia (M6: FAB classification) following treatment with alkylating agents (a total of 2, 500 mg of melphalan and 9, 800 mg of cyclophosphamide). Chromosome analysis of the bone marrow showed 49, XX, der(1;7)(q10;p10), +8, +19, +21 in therapy-related myelodysplastic syndrome with additional chromosomes 8, and 12 and two additional chromosomes 21 in acute leukemia. Because of the risk of therapy-related leukemia, alky lating agents should be used with caution in the treatment of Crow-Fukase syndrome.
(Internal Medicine 35: 660-662, 1996)